FERTILITY IN WOMEN WITH PHARMACOLOGICAL TREATMENT OF OBESITY DISEASE- REVIEW AND ANALYSIS OF CURRENT CLINICAL DATA

Barbara Reizer; Jagoda  Bartman- Białek; Wiktoria  Dusiłło; Jakub Krzysztof  Kruk

doi:10.31435/ijitss.1(49).2026.4593

Authors

Barbara Reizer Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0009-7890-1443
Jagoda Bartman- Białek Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0000-8933-2519
Wiktoria Dusiłło University of Rzeszów, Rzeszów, Poland https://orcid.org/0009-0006-1764-3100
Jakub Krzysztof Kruk Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0002-8027-0520

DOI:

https://doi.org/10.31435/ijitss.1(49).2026.4593

Keywords:

Obesity, Pharmacotherapy, Female Fertility, PCOS, Weight Reduction, Hormonal Contraception, Periconceptional Period, Interdisciplinary Approach, Infertility Treatment, Drug Safety

Abstract

Background: Obesity is one of the key factors negatively affecting female fertility, disrupting hormonal function, ovulation and oocyte quality. In recent years, the development pharmacotherapy for obesity-related disease has opened up new treatment options for patients with excessive body weight, especially in those with polycystic ovary syndrome (PCOS) and insulin resistance. The purpose of this article is to review current clinical data on the effects of pharmacological treatment of obesity on improving reproductive parameters and the safety of drugs in women of reproductive age. Both the therapeutic benefits of weight reduction and the potential risks, including ethical aspects and limitations in the use of drugs during the periconceptional period, are discussed. The need for a multidisciplinary approach involving the cooperation of gynecologists, endocrinologists, nutritionists and psychologists is also pointed out, increasing the effectiveness and safety of treatment

Aim: The purpose of this paper is to present and analyze current clinical data on the impact of pharmacotherapy used in the treatment of obesity on female fertility, with particular emphasis on hormonal mechanisms, the efficacy of individual drugs, the safety of their use during the periconceptional period, and the importance of a multidisciplinary approach in the treatment of overweight women planning a pregnancy.

Materials and methods: The paper is a narrative review. A literature search was conducted in databases to gather current scientific data on the effects of pharmacological treatment of obesity on female fertility: PubMed, Scopus, Google Scholar and the Cochrane Library. Publications were selected with a focus on clinical trials, systematic reviews, guidelines of scientific societies and meta-analyses.

Results: Pharmacotherapy for obesity is a promising tool for treating infertility in overweight women, although it requires further clinical trials and individualization of therapy.

References

Vigil, P., Blackwell, L. F., & Cortés, M. E. (2012). The importance of fertility awareness in the assessment of a woman’s health: A review. The Linacre Quarterly, 79(4), 426–450.

Tsatsoulis, A., & Paschou, S. A. (2020). Female reproductive dysfunction in obesity and the role of the hypothalamic–pituitary–ovarian axis. Hormones, 19(2), 123–131.

Escobar-Morreale, H. F. (2021). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 17(9), 548–561.

Luk, B., & Loke, A. Y. (2015). The impact of infertility on the psychological well-being, marital relationships, sexual relationships, and quality of life of couples: A systematic review. Journal of Sex & Marital Therapy, 41(6), 610–625.

Silvestris, E., de Pergola, G., Rosania, R., & Loverro, G. (2018). Obesity as disruptor of the female fertility. Reproductive Biology and Endocrinology, 16(1), Article 22.

Cleveland Clinic. (2023). Obesity: What it is, types, causes & treatment.

World Health Organization. (2023). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Narodowy Fundusz Zdrowia. (2022). Otyłość i jej konsekwencje.

Verywell Health. (2023). Split opinions on obesity as a disease.

Jungheim, E. S., & Moley, K. H. (2010). Obesity and reproductive function: A review of the evidence. Fertility and Sterility, 94(7), 2181–2187.

Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2011(7), Article CD007506. https://doi.org/10.1002/14651858.CD007506.pub3

Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2017). Obesity: A chronic relapsing progressive disease process. Endocrine Reviews, 38(1), 1–30. https://doi.org/10.1210/er.2016-1030

World Health Organization. (2022). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

World Health Organization. (2008). Waist circumference and waist–hip ratio: Report of a WHO expert consultation. WHO.

Frühbeck, G., Toplak, H., Woodward, E., Yumuk, V., Maislos, M., & Oppert, J. M. (2013). Obesity: The gateway to ill health—An EASO position statement. Obesity Facts, 6(2), 117–120.

Després, J. P. (2012). Body fat distribution and risk of cardiovascular disease: An update. Circulation, 126(10), 1301–1313. https://doi.org/10.1161/CIRCULATIONAHA.111.067264

Björntorp, P. (1988). Abdominal obesity and the development of non-insulin-dependent diabetes mellitus. Diabetes/Metabolism Reviews, 4(6), 615–622. https://doi.org/10.1002/dmr.5610040605

Lemieux, S., Prud’homme, D., Bouchard, C., Tremblay, A., & Després, J. P. (1996). A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. The American Journal of Clinical Nutrition, 64(5), 685–693. https://doi.org/10.1093/ajcn/64.5.685

Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298. https://doi.org/10.1038/s41574-019-0176-8

Loos, R. J. F., & Yeo, G. S. H. (2022). The genetics of obesity: From discovery to biology. Nature Reviews Genetics, 23(2), 120–133. https://doi.org/10.1038/s41576-021-00414-z

Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505), 425–432. https://doi.org/10.1038/372425a0

Dallman, M. F., Pecoraro, N. C., & la Fleur, S. E. (2005). Chronic stress and comfort foods: Self-medication and abdominal obesity. Brain, Behavior, and Immunity, 19(4), 275–280. https://doi.org/10.1016/j.bbi.2004.11.004

Serretti, A., & Mandelli, L. (2010). Antidepressants and body weight: A comprehensive review and meta-analysis. Journal of Clinical Psychiatry, 71(10), 1259–1272. https://doi.org/10.4088/JCP.09r05346blu

Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nature Reviews Immunology, 11(2), 85–97. https://doi.org/10.1038/nri2921

Ahima, R. S., & Flier, J. S. (2000). Leptin. Annual Review of Physiology, 62(1), 413–437. https://doi.org/10.1146/annurev.physiol.62.1.413

Tena-Sempere, M. (2007). Feeding the reproductive axis: Environmental and metabolic signals. Human Reproduction Update, 13(6), 575–587.

Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444(7121), 860–867. https://doi.org/10.1038/nature05485

Diamanti-Kandarakis, E., & Papavassiliou, A. G. (2006). Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends in Molecular Medicine, 12(7), 324–332. https://doi.org/10.1016/j.molmed.2006.05.006

Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009). Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and PCOS Society. Fertility and Sterility, 92(6), 1966–1982.

Goldsammler, M., Merhi, Z., & Buyuk, E. (2018). Role of hormonal and inflammatory alterations in obesity-related reproductive dysfunction at the level of the hypothalamic-pituitary-ovarian axis. Reproductive Biology and Endocrinology, 16, Article 45. https://doi.org/10.1186/s12958-018-0366-6

Pan, H., Guo, J., & Su, Z. (2014). Advances in understanding the interrelations between leptin resistance and obesity. Physiology & Behavior, 130, 157–169. https://doi.org/10.1016/j.physbeh.2014.03.010

Esser, N., Paquot, N., & Scheen, A. J. (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Diabetes & Metabolism, 41(6), 397–405. https://doi.org/10.1016/j.diabet.2015.02.006

Azziz, R., Carmina, E., Chen, Z., et al. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, Article 16057. https://doi.org/10.1038/nrdp.2016.57

Barber, T. M., Hanson, P., Weickert, M. O., & Franks, S. (2019). Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies. Clinical Medicine Insights: Reproductive Health, 13, 1179558119874042. https://doi.org/10.1177/1179558119874042

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25. https://doi.org/10.1016/j.fertnstert.2003.10.004

Lim, S. S., Norman, R. J., Davies, M. J., & Moran, L. J. (2013). The effect of obesity on polycystic ovary syndrome: A systematic review and meta-analysis. Obesity Reviews, 14(2), 95–109. https://doi.org/10.1111/j.1467-789X.2012.01053.x

Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., et al. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews, 36(5), 487–525. https://doi.org/10.1210/er.2015-1018

Vitek, W. S., & Hoeger, K. M. (2020). Obesity and reproductive dysfunction: A review of the evidence. Current Opinion in Obstetrics and Gynecology, 32(3), 173–179.

Teede, H. J., Misso, M. L., Costello, M. F., et al. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602–1618. https://doi.org/10.1093/humrep/dey256

Pasquali, R., Gambineri, A., & Pagotto, U. (2006). The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG, 113(10), 1148–1159. https://doi.org/10.1111/j.1471-0528.2006.01090.x

Luzzo, K. M., Wang, Q., Purcell, S. H., et al. (2012). High fat diet induced developmental defects in the mouse: Oocyte meiotic aneuploidy and fetal growth retardation. Biology of Reproduction, 87(4), Article 73.

Jungheim, E. S., Schon, S. B., Schulte, M. B., et al. (2013). IVF outcomes in obese donors: Reduced oocyte quality, endometrial receptivity, and embryo quality. Fertility and Sterility, 100(6), 1570–1575.

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., et al. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362. https://doi.org/10.1210/jc.2014-3415

Hutton, B., Fergusson, D., Wu, P., Yazdi, F., Bassler, D., Kazemi, M., et al. (2016). Orlistat for weight loss in adults. Cochrane Database of Systematic Reviews, 2016(3), Article CD003641. https://doi.org/10.1002/14651858.CD003641.pub4

Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361

Jayagopal, V., Kilpatrick, E. S., Holding, S., Jennings, P. E., & Atkin, S. L. (2005). Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. Journal of Clinical Endocrinology & Metabolism, 90(2), 729–733. https://doi.org/10.1210/jc.2004-0176

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., et al. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes randomized clinical trial. JAMA, 314(7), 687–699. https://doi.org/10.1001/jama.2015.9676

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009). Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocrine Reviews, 30(1), 1–50. https://doi.org/10.1210/er.2008-0030

Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., et al. (2009). Rational design of a combination medication for the treatment of obesity. Obesity, 17(1), 30–39. https://doi.org/10.1038/oby.2008.448

Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O’Neil, P. M., et al. (2011). Weight loss with naltrexone-bupropion combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity, 19(1), 110–120. https://doi.org/10.1038/oby.2010.147

Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R. (2022). Naltrexone plus bupropion combination medication and behavior therapy, alone and combined, for binge-eating disorder: Randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 179(12), 927–937. https://doi.org/10.1176/appi.ajp.20220267

Grundy, S. M. (2004). Obesity, metabolic syndrome, and cardiovascular disease. Journal of Clinical Endocrinology & Metabolism, 89(6), 2595–2600.

Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015). Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocrine Research, 40(3), 133–138. https://doi.org/10.3109/07435800.2014.966385

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomized trials. The Lancet Diabetes & Endocrinology, 7(10), 776–785.

Gambineri, A., Patton, L., Altieri, P., et al. (2004). Polycystic ovary syndrome is a risk factor for type 2 diabetes: Results from a long-term prospective study. Diabetes, 53(3), 785–791.

Brownley, K. A., Berkman, N. D., Sedway, J. A., Lohr, K. N., & Bulik, C. M. (2007). Binge eating disorder treatment: A systematic review of randomized controlled trials. International Journal of Eating Disorders, 40(4), 337–348.

U.S. Food and Drug Administration. (2023). Drug safety communication: FDA warns about risks of use of GLP-1 receptor agonists in pregnancy.

Glueck, C. J., & Wang, P. (2002). Metformin during pregnancy and lactation in women with the polycystic ovary syndrome: Medical therapy without fetal or neonatal toxicity. Journal of Laboratory and Clinical Medicine, 140(3), 169–176.

Thom, G., & Lean, M. E. J. (2017). Is there an optimal diet for weight management and metabolic health? Gastroenterology, 152(7), 1739–1751.

Compher, C. W., & Badell, M. L. (2016). Pregnancy after bariatric surgery. Clinical Obstetrics and Gynecology, 59(1), 136–145.

DeMarco, L. M., & Berry, D. C. (2013). Ethical issues in the treatment of obesity in women of childbearing age. Journal of Midwifery & Women’s Health, 58(5), 489–495.

Legro, R. S., Dodson, W. C., Kunselman, A. R., et al. (2016). Benefit of delayed fertility treatment with preconception weight loss in obese women with PCOS. Journal of Clinical Endocrinology & Metabolism, 101(7), 2658–2666.

Beauchamp, T. L., & Childress, J. F. (2013). Principles of biomedical ethics (7th ed.). Oxford University Press.

Lyerly, A. D., Little, M. O., & Faden, R. R. (2008). The second wave: Toward responsible inclusion of pregnant women in research. International Journal of Feminist Approaches to Bioethics, 1(2), 5–22.